New adjuvants: EU regulatory developments

References

• Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine23, 3210–3222 (2005).
   PubMed Web of Science ®Google Scholar
• Sesardic D, Corbel MJ. Pre-clinical evaluation and quality control aspects of microparticulate antigen delivery systems. In: Antigen Delivery Systems: Immunological and Technical Issues. Gander B, Merkle HP, Corradin H (Eds). Harwood Academic Press, London, UK 227–250 (1997).
   Google Scholar
• Sesardic D, Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine22, 2452–2456 (2004).
   PubMed Web of Science ®Google Scholar
• Verdier F. Non-clinical vaccine safety assessment. Toxicology174, 37–43 (2002).
   PubMed Web of Science ®Google Scholar
• The European Pharmacopoeia Commission. General Monograph: Vaccines for Human Use (4th Edition) (2002).
   Google Scholar
• World Health Organization Guidelines on clinical evaluation of vaccines: regulatory expectations. In: WHO Expert Committee on Biological Standardization (52nd Report).WHO Technical Report Series, No 924, Annex 1 (2004)
   Google Scholar
• World Health Organization Guidelines on non-clinical evaluation of vaccines. In: WHO Expert Committee on Biological Standardization (54th Report). WHO Technical Report Series No 927, Annex 1 (2005).
   Google Scholar
• ICH Document S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (CPMP/ICH/302/95).
   Google Scholar
• ICH Document E6: Guideline for Good Clinical Practice(CPMP/ICH/135/95).
   Google Scholar
• ICH Document E8: General Considerations for Clinical Trials. (CPMP/ICH/291/95).
   Google Scholar
• US FDA. Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology (1985).
   Google Scholar
• Glenny AT, Pope CG, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium–alum. J. Path. Bact.29, 38–45 (1926).
   Google Scholar
• Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Immunological Adjuvants and Vaccines. Gregoriades G, Allison AC, Poste G (Eds). Plenum Press, NY, USA 35–41 (1989).
   Google Scholar
• Gupta RK, Siber RG. Adjuvants for human vaccines – current issues, problems and future prospects. Vaccine13, 1263–1276. (1995).
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminium compounds as vaccine adjuvants. Adv. Drug Deliv. Rev.32, 155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Brewer JM, Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell. Mol. Ther.3, 233–246 (1997).
   PubMedGoogle Scholar
• Brewer JM. (How) do aluminium adjuvants work. Immunol. Lett.102, 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Schijns VEJC. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol.12, 456–463 (2000).
   PubMed Web of Science ®Google Scholar
• Edelman R. The development and use of vaccine adjuvants. Mol. Biotechnol.21, 129–148 (2002).
   PubMed Web of Science ®Google Scholar
• Kenny RT, Edelman R. Survey of human-use adjuvants. Expert. Rev. Vaccines2, 167–188 (2003).
   PubMedGoogle Scholar
• Vogel FR. Immunological adjuvants for modern vaccine formulations. Ann. NY Acad. Sci.31, 754–760 (1995).
   Google Scholar
• Dougan G, Hormaeche C. How bacteria and their products provide clues to vaccine and adjuvant development. Vaccine12(Suppl. 2), S2–S13 (2006).
   Google Scholar
• Del Giudice G, Podda A, Rappouli R. What are limits of adjuvanticity? Vaccine20, S38–S41 (2001).
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol.82, 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines2, 285–293 (2003).
   PubMedGoogle Scholar
• Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine20, B10–B16 (2002).
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11, S63–S68 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Review: vaccine adjuvants revisited. Vaccine25, 3752–3762 (2007).
   PubMed Web of Science ®Google Scholar
• Singh M and O’Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res.19, 715–728 (2002).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines2(2), 253–267 (2003).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Orenstein WA, Offit PA. Safety of vaccines. In: Vaccines (3rd Edition). Saunders, PA, USA, 18–33 (1999).
   Google Scholar
• McDonald R, Mohrs M, Brewer J. Using bicistronic IL-4 reporter in mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant. Vaccine24, 5393–5399 (2006).
   PubMed Web of Science ®Google Scholar
• Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In IL-4 deficient mice, alum not only generates T-helper-1 responses equivalent to Freund’s complete adjuvant, but continues to induce T helper-2 cytokine production. Eur. J. Immunol.26, 2062–2066 (1996).
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J-L, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine11, 914–918 (1993).
   PubMed Web of Science ®Google Scholar
• Andre FE. Vaccinology: past achievements, present roadblocks and WHO future promises. Vaccine21, 593–595 (2003).
   PubMed Web of Science ®Google Scholar
• Brenner A. Macrophagic myofasciitis: a summary of Dr Gherardi’s presentations. Vaccine20(Suppl. 3), S5–S6 (2002).
   PubMedGoogle Scholar
• Park JR, Kieny M-P. Meeting report: 4th Meeting on Novel Adjuvants Currently in Close to Human Clinical Testing. World Health Organization – Organisation Moniale de las Sante Fondation Merieux, Annecy, France, 23–25 June 2003. Vaccine22, 2097–2102 (2004).
   PubMedGoogle Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R; Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine25(20), 3955–3961 (2007).
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17(2), 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol.17(2), 135–140 (2001).
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Mariutto Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine19(25–26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis.43, 1135–1142 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357(9272), 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Gluck R, Walti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel)103, 189–197. (2000).
   PubMedGoogle Scholar
• Salleras L, Dominguez A, Pumarola T et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: a prospective cohort study. Vaccine24, 6638–6642 (2006).
   PubMed Web of Science ®Google Scholar
• Kursteiner O, Moser C, Lazar H, Durrer P. Inflexal V – the influenza vaccine with the lowest ovalbumin content. Vaccine24, 6632–6635 (2006).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine18(20), 2095–2101 (2000).
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine16(7), 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Eng. J. Med.350, 860–861 (2004).
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis.181, 1129–1132 (2000).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   Google Scholar
• Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand.81, 103–107 (1993).
   PubMedGoogle Scholar
• Takahashi H, Pool V, Tsai1 TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine18, 2963–2969 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med.344, 564–572 (2001).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions J. Infect. Dis.187, 1309–1313 (2003).
   PubMed Web of Science ®Google Scholar
• Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal L121, 34–44 (2001).
   Google Scholar
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Official Journal L311, 67–128 (2001).
   Google Scholar
• Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine20, S56–S64 (2002).
   PubMed Web of Science ®Google Scholar
• Durrer P, Gluck U, Spyr C et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine21, 4328–4334 (2003).
   PubMed Web of Science ®Google Scholar
• Frech SA, Kenney RT, Spyr CA et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine23(7), 946–950 (2005).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med.6, 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine25, 3684–3691 (2007).
   PubMed Web of Science ®Google Scholar
• Guerena-Burgueno F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun.70, 1874–1880 (2002).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol.80(10), 4962–4970 (2006).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood89(9), 3129–3135 (1997).
   PubMed Web of Science ®Google Scholar
• Jacques P, Moens G, Desombere I et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine20(31–32), 3644–3649 (2002).
   PubMed Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine23(3), 316–320 (2004).
   PubMed Web of Science ®Google Scholar
• Desombere I, Van der Wielen M, Van Damme P et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine20(19–20) 2597–2602 (2002).
   PubMed Web of Science ®Google Scholar
• Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68(5), 2298–2303 (2005).
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Aoki FY, Tyring SK et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis.40(9) 1271–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364, 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Harper D, Franco E, Wheeler C et al. Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health40(6), 564–571 (2007).
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Bernstein H, Pelton S et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine20(31–32), 3658–3667 (2002).
   PubMed Web of Science ®Google Scholar
• Moutschen M, Leonard P, Sokal EM et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. Vaccine25(24), 4697–4705 (2007).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine23(20), 2591–2601 (2005).
   PubMed Web of Science ®Google Scholar
• Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg.61, 865–868 (1999).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358, 1927–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis.183(4), 640–647 (2001).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Heppner DG Jr, Mason CJ et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am. J. Trop. Med. Hyg.75(1), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364, 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine23(32), 4148–4157 (2005).
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Angov E, Kester KE et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine24(15), 3009–3017 (2006).
   PubMed Web of Science ®Google Scholar
• Withers MR, McKinney D, Ogutu BR et al. Safety and Reactogenicity of an MSP-1 Malaria vaccine candidate, a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin. Trials1(7), e32 (2006).
   PubMedGoogle Scholar
• Polhemus ME, Magill AJ, Cummings JF et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine (21), 4203–4212 (2007).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Barrasso R, Meijer CJ et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J. Infect. Dis.192(12), 2099–107 (2005).
   PubMed Web of Science ®Google Scholar
• Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother.29(5), 558–568. (2006).
   PubMed Web of Science ®Google Scholar
• Evans TG, McElrath MJ, Matthews T et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine19(15–16), 2080–2091 (2001).
   PubMed Web of Science ®Google Scholar
• Mbawuike I, Zang Y, Couch RB. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine25(17), 3263–3269 (2007).
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Kublin JG et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine21(3–4), 269–280 (2002).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine17(22), 2769–2778 (1999).
   PubMed Web of Science ®Google Scholar
• Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine21(27–30), 4234–4237 (2003).
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine21, 1268–1274 (2003).
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine24(Suppl. 2), S44–S45 (2006).
   Web of Science ®Google Scholar
• Saul A, Lawrence G, Smillie A et al. Human Phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine17, 3145–3159 (1999).
   PubMed Web of Science ®Google Scholar
• Morita S, Oka Y, Tsuboi A et al. A Phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J. Clin. Oncol.36(4), 231–236 (2006).
   PubMed Web of Science ®Google Scholar
• Wang F, Bade E, Kuniyoshi C et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin. Cancer Res.10, 2756–2765 (1999).
   Google Scholar
• Lee P, Wang F, Kuniyoshi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol.19(18), 3836–3847 (2001).
   PubMed Web of Science ®Google Scholar